Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Vidya Maiya"'
Autor:
Zia Khan, Min Jung, Megan Crow, Rajat Mohindra, Vidya Maiya, Joshua S. Kaminker, David H. Hackos, G. Scott Chandler, Mark I. McCarthy, Tushar Bhangale
Publikováno v:
Genome Medicine, Vol 15, Iss 1, Pp 1-15 (2023)
Abstract Background Dose-limiting toxicities significantly impact the benefit/risk profile of many drugs. Whole genome sequencing (WGS) in patients receiving drugs with dose-limiting toxicities can identify therapeutic hypotheses to prevent these tox
Externí odkaz:
https://doaj.org/article/8203af64f2254efdb0211f8800973199
Autor:
Katrin Madjar, Rajat Mohindra, Gonzalo Durán-Pacheco, Rashad Rasul, Laurent Essioux, Vidya Maiya, G. Scott Chandler
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer patients in the last decade, but immune-related adverse events (irAEs) pose significant clinical challenges. Despite advances in the management of these unique
Externí odkaz:
https://doaj.org/article/3908e581aa5f492fbf36449ebc775e8e
Autor:
Zia Khan, Christian Hammer, Jonathan Carroll, Flavia Di Nucci, Sergio Ley Acosta, Vidya Maiya, Tushar Bhangale, Julie Hunkapiller, Ira Mellman, Matthew L. Albert, Mark I. McCarthy, G. Scott Chandler
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Endocrinopathies, such as thyroid autoimmunity, are common among patients treated with immune checkpoint inhibitors. Here, by using a polygenic risk score (PRS) derived from a hypothyroidism GWAS, the authors show that cancer patients with high PRS a
Externí odkaz:
https://doaj.org/article/c4d618dc88c448e799c4accf705c951a
Autor:
Zia Khan, Min Jung, Megan Crow, Rajat Mohindra, Vidya Maiya, Joshua Kaminker, David Hackos, G. Scott Chandler, Mark McCarthy, Tushar Bhangale
Dose-limiting toxicities significantly impact the benefit/risk profile of many drugs. Whole genome sequencing (WGS) in patients receiving drugs with dose-limiting toxicities can identify therapeutic hypotheses to prevent these toxicities. Peripheral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::475494e22eba51cbe498b2e4669edc38
https://doi.org/10.21203/rs.3.rs-1816977/v1
https://doi.org/10.21203/rs.3.rs-1816977/v1
Autor:
Zanete Zvirbule, Marion Monchalin, Nadia Tosti, Kunihiko Tanaka, Emanuela Pozzi, Eleonora Restuccia, Pascal Chanu, Enriqueta Felip, Vidya Maiya, Phyllis Chan, Bei Wang, Luis A. Herráez-Baranda, Smita Kshirsagar, Mathilde Marchand, Mauricio Burotto
Publikováno v:
Clinical Pharmacology in Drug Development
Intravenous (IV) atezolizumab is approved for non–small cell lung and other cancers. Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase, a permeation enhancer for SC dispersion and absorption, is being developed to imp
Autor:
Leisha A. Emens, Peter Schmid, Hope S. Rugo, IMpassion Investigators, Véronique Diéras, Stephen Y. Chui, Carlos H. Barrios, Hiroji Iwata, Vidya Maiya, Sherene Loi, Andreas Schneeweiss, Volkmar Henschel, Amreen Husain, Luciana Molinero, Eric P. Winer, Sylvia Adams
Publikováno v:
Ann Transl Med
Summary Background Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim overall survival analysis of the phase 3 IMpassion130 study assessing the eff
Autor:
Luciana Molinero, Christopher J. Darus, Xiaohua Wu, Johanna Mäenpää, Charles K. Anderson, Nicoletta Colombo, Aikou Okamoto, Giovanni Scambia, Y. García, Fan Wu, Michael A. Bookman, Yvonne G. Lin, Victor Khor, L. Willmott, Jalid Sehouli, Tashanna Myers, Michalis Liontos, Rustem Safin, Michael A. Gold, Cagatay Taskiran, Katina Robison, Austin Miller, Vidya Maiya, Sudarshan K. Sharma, Carol Aghajanian, Sandro Pignata, Jessica Thomes-Pepin, Kathleen N. Moore
Publikováno v:
J Clin Oncol
Journal of Clinical Oncology
Journal of Clinical Oncology
Purpose: to evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). Methods: this multicent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea89f9ab83f69d1132450dbd7ec3832
http://hdl.handle.net/10281/327598
http://hdl.handle.net/10281/327598
Autor:
Luciana Molinero, Melinda L. Telli, Vidya Maiya, Hiroji Iwata, Kevin Punie, Mario Liste-Hermoso, Carlos H. Barrios, Andreas Koehler, Elizabeth A. Mittendorf, Frédérique Penault-Llorca, Shilpen Patel, Anh Nguyen Duc, Cristiano Ferrario, Joohyuk Sohn, Roberto Hegg, Shigehira Saji, Stephen Y. Chui, Kyung Hae Jung, Nadia Harbeck, Hong Zhang
Publikováno v:
The Lancet
The Lancet, Elsevier, 2020, 396 (10257), pp.1090-1100. ⟨10.1016/S0140-6736(20)31953-X⟩
The Lancet, Elsevier, 2020, 396 (10257), pp.1090-1100. ⟨10.1016/S0140-6736(20)31953-X⟩
Summary Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 compared efficacy and safety of atezolizumab versus placebo comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221e52d5af8d01ad9b7f0473fadec775
https://hal.archives-ouvertes.fr/hal-03046446
https://hal.archives-ouvertes.fr/hal-03046446
Autor:
Enriqueta Felip, Vidya Maiya, Emanuela Pozzi, Eleonora Restuccia, Smita Kshirsagar, M. Burotto, Pascal Chanu, Z. Zvirbule, L.A. Herraez Baranda
Publikováno v:
Annals of Oncology. 31:S820-S821
Autor:
Cristiano Ferrario, Shigehira Saji, Luciana Molinero, Kevin Punie, A. Nguyen Duc, Melinda L. Telli, Hong Zhang, S.Y. Chui, Carlos H. Barrios, Mario Liste-Hermoso, Kyung Hwa Jung, Nadia Harbeck, H. Iwata, Joohyuk Sohn, A. Koehler, Vidya Maiya, Elizabeth A. Mittendorf, Roberto Hegg, Sheetal Patel, Frédérique Penault-Llorca
Publikováno v:
Annals of Oncology. 31:S1144